7 Early Decisions That Can Make — or Delay — Your Clinical Trial

Why successful clinical trials begin long before the first patient is enrolled

When clinical trial delays are discussed, patient recruitment is often the first challenge that comes to mind.

In reality, many delays begin much earlier.

Long before the first patient is enrolled, the decisions made during study planning influence every stage of a clinical trial—from regulatory submissions and site activation to recruitment timelines, operational efficiency and data quality.

Although no clinical trial is completely free from unexpected challenges, careful planning during study start-up can significantly reduce avoidable delays.

The strongest clinical trials are often built on the decisions made before study start-up even begins.

At a Glance: Seven Early Decisions That Shape Study Success

Each of these decisions may seem independent, but together they determine how efficiently a clinical trial moves from planning to execution.

1. Design a Protocol That Works Beyond the Scientific Theory

Every successful clinical trial begins with a well-designed protocol.

Scientific quality is essential, but operational feasibility is equally important. Even the strongest scientific rationale can be undermined by eligibility criteria that are too restrictive, unnecessary assessments or visit schedules that are difficult for both investigators and patients.

A protocol should answer two questions:

• Will it achieve the study objectives?
• Can it realistically be implemented at participating sites?

Finding the balance between scientific rigour and operational practicality is often one of the most valuable decisions made during study start-up.

2. Treat Feasibility as More Than a Checklist

Feasibility is not simply confirming that a site is interested.

It is the process of understanding whether the study can realistically be delivered under the proposed conditions.

A robust feasibility assessment typically considers:

• Availability of eligible patients
• Investigator experience
• Competing clinical studies
• Site resources and staffing
• Local operational considerations

The objective is not simply to identify willing sites, but the right sites.

Strong feasibility creates realistic expectations from the very beginning.

3. Engage Research Sites Earlier Than You Think

Many experienced investigators participate in multiple studies simultaneously.

Waiting until every document has been finalised before contacting sites can reduce availability and extend activation timelines.

Early conversations with investigators often provide valuable feedback that improves protocol execution and identifies practical challenges before regulatory submissions begin.

Site selection is not only about geography.

It is about building the right operational network for the study.

4. Plan Regulatory Activities as Part of the Project — Not as a Separate Step

Regulatory preparation is frequently viewed as a milestone.

In reality, it is an ongoing process that should evolve alongside study planning.

Preparing submission packages, reviewing essential documentation and coordinating country-specific requirements all require time and close collaboration between multiple functions.

Regulatory planning should also be aligned with Good Clinical Practice (GCP) principles and applicable regulatory requirements.

Proactive planning reduces unnecessary revisions and supports more predictable study start-up timelines.

5. Start Thinking About Recruitment Before Recruitment Starts

Successful recruitment rarely depends on luck.

It begins during protocol development.

Understanding where eligible patients are treated, what competing studies exist and what barriers may affect participation allows sponsors to develop more realistic recruitment strategies.

The first patient is recruited long before the first screening visit.

It starts with good planning.

6. Coordinate Every Function from Day One

Study start-up involves far more than Clinical Operations.

Regulatory Affairs, Medical Writing, Data Management, Biostatistics, Pharmacovigilance and Project Management all contribute to the same objective.

When each function works independently, small inefficiencies often accumulate into significant delays.

Cross-functional planning improves communication, reduces duplicated work and keeps study preparation moving in the right direction.

Clinical trials succeed when teams move together—not separately.

7. Prioritise Study Readiness, Not Just Study Speed

Launching quickly is important.

Launching before the study is truly ready can generate challenges that are much harder to solve later.

Operational readiness includes:

• Complete documentation
• Clear timelines
• Defined responsibilities
• Identified risks
• Aligned study teams

Sometimes investing a little more time before activation saves considerably more time throughout the study.

What Do These Seven Decisions Have in Common?

Every one of these decisions takes place before the first patient is enrolled.

That is precisely why they matter.

Clinical trial success is rarely determined by a single event.

More often, it is the result of dozens of early decisions that collectively influence timelines, recruitment, data quality and operational performance.

Sponsors who approach study start-up strategically are often better positioned to prevent avoidable delays later in the project.

Building a Stronger Study Start-Up

There is no universal formula for eliminating delays.

However, several practices consistently improve study readiness:

✓ Design operationally feasible protocols.

✓ Perform comprehensive feasibility assessments.

✓ Engage investigators early.

✓ Prepare regulatory documentation proactively.

✓ Develop recruitment strategies during protocol planning.

✓ Coordinate all functional teams from the outset.

✓ Identify operational risks before study activation.

Small decisions made early often have the greatest impact on study success.

Conclusion

Clinical trials do not become successful when recruitment begins.

They become successful long before that.

Every protocol reviewed, every feasibility assessment completed and every operational decision made during study start-up contributes to the efficiency of the study that follows.

By treating study start-up as a strategic phase rather than an administrative process, sponsors can reduce avoidable delays, improve operational performance and build stronger foundations for successful clinical development.

Frequently Asked Questions

What causes delays before a clinical trial begins?

Many delays originate during study start-up, including protocol complexity, inadequate feasibility, regulatory preparation, site activation and operational coordination.

What is study start-up in a clinical trial?

Study start-up is the planning phase between protocol development and the enrolment of the first patient. It includes feasibility assessments, regulatory submissions, site activation, contracts and operational preparation.

Why is feasibility important?

Feasibility helps determine whether a study can realistically achieve its objectives within the proposed timelines while identifying operational risks before activation.

Can protocol design delay a clinical trial?

Yes. Complex protocols may slow ethics approvals, reduce site participation, increase recruitment challenges and lead to protocol amendments during study conduct.

How can sponsors improve study start-up?

Early planning, realistic feasibility, proactive regulatory preparation and strong collaboration between all study functions are among the most effective ways to improve study readiness and reduce avoidable delays.